Neovasc (NVCN)

Company Profile

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.

Company profile

Ticker

NVCN

Exchange

NASDAQ

Website

www.neovasc.com

CEO

Fred Colen

Incorporated

British Columbia, Canada

Location

British Columbia, Canada

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...

Former names

Medical Ventures Corp

SEC CIK

0001399708

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

NVCN stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

6-K

Material Change Report

18 Jan 23

6-K

Current report (foreign)

17 Jan 23

6-K

Shockwave Medical to Acquire Neovasc

17 Jan 23

6-K

Neovasc Announces Progress on COSIRA-II Clinical Trial

28 Nov 22

6-K

Current report (foreign)

18 Nov 22

6-K

Unaudited Condensed Interim Consolidated Financial Statements

10 Nov 22

6-K

Current report (foreign)

8 Nov 22

6-K

Current report (foreign)

27 Oct 22

6-K

Neovasc Provides Corporate Update Following Clinical Data Release

20 Sep 22

6-K

Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit

16 Sep 22

Transcripts

View all

NVCN

Earnings call transcript

2022 Q3

11 Nov 22

NVCN

Earnings call transcript

2022 Q2

12 Aug 22

NVCN

Earnings call transcript

2022 Q1

13 May 22

NVCN

Earnings call transcript

2021 Q3

10 Nov 21

NVCN

Earnings call transcript

2021 Q2

11 Aug 21

NVCN

Earnings call transcript

2021 Q1

7 May 21

NVCN

Earnings call transcript

2020 Q4

12 Mar 21

NVCN

Earnings call transcript

2020 Q3

8 Nov 20

Latest ownership filings

View all

SC 13G/A

CVI Investments, Inc.

14 Feb 22

SC 13D

FiveT Investment Management Ltd

25 Feb 21

SC 13G

INTRACOASTAL CAPITAL, LLC

19 Feb 21

SC 13G

CVI Investments, Inc.

19 Feb 21

SC 13G/A

Magnetar Financial LLC

12 Feb 21

SC 13G/A

SABBY MANAGEMENT, LLC

6 Jan 21

SC 13G

INTRACOASTAL CAPITAL, LLC

17 Dec 20

SC 13G

ARMISTICE CAPITAL, LLC

20 Aug 20

SC 13G

Strul Medical Group, LLC

29 Jun 20

SC 13G

ARMISTICE CAPITAL, LLC

22 Jun 20

Financial summary

Financial statements Chart NVCN financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Neovasc earnings reports.

Institutional ownership, Q2 2022

NVCN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	14	23	-39.1%
Opened positions	1	2	-50.0%
Closed positions	10	4	+150.0%
Increased positions	0	3	EXIT
Reduced positions	10	9	+11.1%

13F shares	Current	Prev Q	Change
Total value	725.94 mm	726.17 mm	-0.0%
Total shares	16.84 mm	17.99 mm	-6.4%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BSX Boston Scientific	11.82 mm	$720.84 mm	0.0%
CVI Investments	2.56 mm	$0.00	0.0%
Intracoastal Capital	2.41 mm	$4.82 mm	0.0%
U.S. Capital Wealth Advisors	18.78 k	$114.00 k	-93.7%
Magnetar Financial	15.80 k	$96.00 k	-96.0%
BAC Bank Of America	3.61 k	$22.00 k	-96.4%
UBS UBS Group AG - Registered Shares	2.97 k	$18.00 k	-37.4%
RY Royal Bank Of Canada	2.36 k	$14.00 k	-46.9%
MS Morgan Stanley	1.43 k	$9.00 k	-98.9%
JPM JPMorgan Chase & Co.	799.00	$5.00 k	-96.4%

Largest transactions	Shares	Bought/sold	Change
Magnetar Financial	15.80 k	-379.41 k	-96.0%
U.S. Capital Wealth Advisors	18.78 k	-281.22 k	-93.7%
MS Morgan Stanley	1.43 k	-124.70 k	-98.9%
Two Sigma Securities	0.00	-108.79 k	EXIT
BAC Bank Of America	3.61 k	-96.15 k	-96.4%
Renaissance Technologies	0.00	-35.41 k	EXIT
Susquehanna International	0.00	-30.55 k	EXIT
JPM JPMorgan Chase & Co.	799.00	-21.44 k	-96.4%
Geode Capital Management	0.00	-21.36 k	EXIT
BKHPF Bank Hapoalim BM	0.00	-19.22 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.